MYK-461

DRUG4 trials

Sponsors

MyoKardia, Inc.

Conditions

Cardiomyopathy, Hypertrophic ObstructiveHealthyHypertrophic CardiomyopathyLeft Ventricular Outflow Tract Obstruction

Phase 1

Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461

CompletedNCT02329184

MyoKardia, Inc.Hypertrophic Cardiomyopathy

Start: 2014-12-31End: 2016-04-30Updated: 2016-09-14

Single Ascending Dose Study of MYK-461 in Healthy Volunteers

CompletedNCT02356289

MyoKardia, Inc.Healthy

Start: 2015-01-31End: 2015-07-31Updated: 2015-09-23

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers

CompletedNCT02480296

MyoKardia, Inc.Healthy

Start: 2015-08-31End: 2016-10-31Updated: 2017-03-22

Phase 2

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

CompletedNCT02842242

MyoKardia, Inc.Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction

Start: 2016-08-31End: 2017-11-30Updated: 2021-06-08

Related Papers

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

CPT Pharmacometrics & Systems Pharmacology2024-05-028 citations

Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study

Journal of the American Heart Association2024-04-0927 citations

228Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study

European Heart Journal2019-10-014 citations

Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.

2019-04-30226 citations

Abstract 24031: Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor

Circulation2017-11-144 citations